STUDY QUESTION: Is the length of the anogenital distance (AGD) a biomarker of ovarian reserve and response to controlled ovarian stimulation (COS)?
Introduction
The ovarian reserve reflects the number of primordial follicles that are non-growing follicles (NGFs), together with follicles recruited into the later preantral and antral stages of development ultimately capable of ovulation. The peak number of primordial follicles reached at 20 weeks gestation has been estimated to be around 10 million. From that moment onwards, atresia starts and progresses continuously, reaching 500,000 follicles at puberty and remaining less than 1000 at the beginning of menopause (Faddy et al., 1992; Wallace and Kelsey, 2010) . Furthermore, as follicle numbers gradually decline with age, a sequence of reproductive events occurs, beginning with reduced fecundity and natural sterility, and progressing through menstrual cycle irregularity towards a complete cessation of menstruation at menopause. The idea that has been developed is that this sequence unfolds according to 'fixed time intervals' between the subsequent stages (te Velde and Pearson, 2002; Broekmans et al., 2009) . Besides, it is well established that organ development during prenatal life is influenced by the prevailing intrauterine environment and it has been suggested that nutritional, environmental and toxic factors could affect ovarian reserve set in the prenatal sphere (Ibanez et al., 2000 (Ibanez et al., , 2002 Mark-Kappeler et al., 2011; Souter et al., 2013) . According to these concepts, three different scenarios may occur: a normal decrease of ovarian reserve with age, a lower ovarian reserve set prenatally with usual postnatal decay, and lower trajectory of ovarian reserve during adverse postnatal environmental or nutritional challenges (Richardson et al., 2014) .
The anogenital distance (AGD) is a sexually dimorphic feature of mammals, usually being longer in males than in females, and a biomarker of prenatal hormonal milieu (Greenham and Greenham, 1977; Kurzrock et al., 2000; Gray et al., 2001) . In observational studies, AGD has been demonstrated as a biomarker of prenatal exposure to endocrine disruptors (Swan et al., 2005; Bornehag et al., 2015) and androgens during the development of the reproductive system (Dean and Sharpe, 2013; Jain and Singal, 2013) . In adult women, AGD length is associated with female reproductive function (Mendiola et al., 2012; Mira-Escolano et al., 2014a,b; Barrett et al., 2015) and gynecology disorders, such as polycystic ovary syndrome (PCOS) (Sanchez-Ferrer et al., 2017; Wu et al., 2017) and endometriosis (Mendiola et al., 2016) .
The goal of this study was to compare the AGD as a biomarker of the hormonal intrauterine environment with conventional ovarian reserve markers and, thereby hypothesize that the ovarian follicular pool could be affected by endocrine disruptors in prenatal life and to assess the relationship between the AGD and the ovarian response to controlled ovarian stimulation (COS).
Materials and methods

Study population
This prospective cohort study was conducted from January to December 2016 in the Assisted Reproduction Department of Hospital Clinic in Barcelona (Spain). A total of 437 patients undergoing their first cycle of COS for IVF/ICSI were included. None of the patients had previous deliveries, ovarian or genital surgery or history of oncological treatment. Patients with a history of previous hormonal treatments during the six months previous to the treatment cycle were excluded. Patients with PCOS and endometriosis were also excluded from the study, as it has been recently published that both entities present changes in the AGD (Mendiola et al., 2016; Sanchez-Ferrer et al., 2017) . After oocyte retrieval, patients were divided into three groups based on the number of oocytes obtained: poor ovarian responders (≤3 oocytes) (n = 50), normoresponders (4-15 oocytes) (n = 332) and high responders (>15 oocytes) (n = 55).
Ethical approval
All patients gave informed consent to participate in the study, which was approved by the Ethics Research Committee of the Hospital Clinic of Barcelona, Spain (Protocol Number: HCB/2014/1130).
Ovarian stimulation protocol
The ovarian stimulation protocol and the gonadotropin doses were chosen according to age and ovarian reserve markers in an individualized manner (La Marca and Sunkara, 2014; Grisendi and La Marca, 2017) . Either the long agonist or the antagonist protocols were used. Ovarian stimulation was achieved with daily doses from 150 to 300 IU of recombinant human follicular stimulating hormone (FSH) (Gonal-F; Merck-Serono S.A., Madrid, Spain), depending on patients characteristics.
Hormone analyses and ultrasonography
Hormones were measured using commercially available kits. FSH serum concentrations were assessed by a chemiluminescent assay (ADVIA Centaur CP System; Siemens Healthcare Diagnostics, Deerfield, IL, USA). The serum anti-Müllerian hormone (AMH) concentration was measured using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (AMH ELISA; Ansh Labs, UK). Ultrasound scans were performed using a Toshiba Eccocee SAA-340A/EF unit (Toshiba Co., Tokyo, Japan) equipped with a 5-7 MHz endovaginal probe (PVF-641VT). Antral follicle count (AFC) was assessed by an expert sonographer between the second and fifth day of the menstrual cycle. The total number of follicles with a mean diameter of 2-9 mm were counted. Ovarian sensitivity index (OSI) was calculated as oocyte yield × 1000/total dose of FSH (Li et al., 2014) .
Anogenital distance and other anthropometric measurements
Anthropometric parameters such as weight (kilograms) and height (meters) were obtained for each patient. BMI was calculated as weight divided by the square of height. Both AGD distances were measured in all patients under sedation on the day of retrieval and before proceeding to oocyte pick-up. Women rested in the lithotomy position with thighs at 45°t o the examination (anus-clitoris) was measured from the anterior clitoral surface to the center of the anus, and AGD AF (anus-fourchette) was measured from the posterior fourchette to the center of the anus (Wu et al., 2017) . Two gynecologists who were unaware of the patient's status measured each distance three times and the mean values were calculated for both distances.
Statistics
For statistical analyses, Student T-test, and Pearson's correlation coefficient were used as appropriate. The arithmetic mean, standard error (SE) and 95% confidence interval (CI) constituted the descriptive analysis. Multiple linear regression analyses were performed to evaluate associations between AGD and other clinical parameters (AMH, AFC, number of oocytes obtained, total doses of gonadotropins and OSI). Logistic regression was used to predict the chance of poor response after COS for IVF/ICSI. The discrimination attained between ovarian reserve markers and AGD was evaluated with receiver operating characteristic (ROC) analysis (Hanley and McNeil, 1982; Zweig and Campbell, 1993) . Sensitivity, specificity, and the area under the ROC curve (AUC) were obtained for each model and were compared using the method of Hanley and McNeil, 1992 . All tests were two-tailed, and P < 0.05 was considered statistically significant. Data were analyzed by Statistics Package for Social Sciences, version 23.0 (SPSS; Chicago, IL, USA) and MedCalc Software (Mariakarke, Belgium). GAM procedures were calculated using MGCV package.
Results Table I shows the main characteristics of the study patients, including their ovarian reserve markers and ovarian stimulation outcomes according to ovarian response. The mean (±SE) age of the women were significantly different among the poor responders, normoresponders and high responders: 37.9 ± 0.9 vs. 36.8 ± 0.4 and 36.1 ± 0.5 years, respectively (P < 0.001). Nevertheless, the BMI were comparable among the three groups: 23.8 ± 1.07 vs. 22.2 ± 0.3 and 21.1 ± 0.6 (non-significant (NS)). Patient indications for IVF/ICSI were similar for the three groups studied. Baseline FSH, AMH and AFC were significantly different in all three groups (P < 0.001), as were the number of retrieved oocytes, the total FSH units used during ovarian stimulation and the OSI (P < 0.001) ( Table I ). The distributions of both AGD AC and AGD AF were approximately normal ( Values are mean ± SE or n (%), OHSS; ovarian hyperstimulation syndrome.
correlation (r = 0.37, P < 0.05), and there was a statistically significant positive association between both AGD measures and BMI (r = 0.25 and r = 0.20, respectively; P < 0.01). AGD AC and AGD AF were positively correlated with AMH levels (r = 0.38 and r = 0.21; P < 0.05), AFC (r = 0.41 and r = 0.20; P < 0.05) (Fig. 2 ) and the OSI (r = 0.24, r = 0.19; P < 0.05), and presented a negative correlation with the total FSH units used (r = -0.19 and r = -0.15; P < 0.05).
As seen in Table II , shorter AGD AC and AGD AF were associated with poor ovarian response. The present study found a significant positive association between both AGD measurements in the three groups of ovarian response (P < 0.001), although no differences were found between the AGD AF of normoresponders and high responders. Besides, both AGD AC and AGD AF presented a positive and significant correlation with the total number of oocytes retrieved (r = 0.29 and r = 0.28, respectively; P < 0.05). Table III shows univariate logistic regression analysis probability estimates for basal FSH, AFC, AMH levels, AGD AC and AGD AF as predictors of poor ovarian response after having accounted for confounders. AGD AC with a prognostic reliability of 74.59%, had a predictive value for poor response comparable to basal FSH, AMH levels and AFC. However, AGD AF with a prognostic reliability of 39.13% had a significantly worse predictive capacity than AFC and AMH.
The predictive value of the multivariable logistic regression analysis, including AGD and the two ovarian reserve tests (AMH and AFC) was not significantly better than that of a simple ovarian reserve test, when used in isolation.
With regard to the diagnostic accuracy of AGD AC measurements for poor response, the AUC AC was 0.70 (95% CI 0.66-0.75) (Fig. 3) with an optimal cut-off of the predicted probability of 93.91 mm. The sensitivity of this model was 62%, specificity was 76.23% and the positive and negative likelihood ratios were 2.61 and 0.50, respectively. The AUC for basal FSH, AMH, AFC and AGD are shown in Fig. 4 .
Discussion
This is the first study reporting an association between AGD in adult human females and their ovarian response after COS for IVF/ICSI. A shorter AGD was significantly associated with the presence of poor response.
The success of assisted reproductive techniques (ART) depends on the ability of the ovaries to respond to gonadotropin stimulation and to develop several follicles leading to adequate oocyte yield. That response reflects the ovarian reserve and depends on the pool of primordial follicles in the ovaries (Penarrubia et al., 2005a,b; Wallace and Kelsey, 2010; Hansen et al., 2011) . Although serum biomarkers and ultrasonographic tests provide an estimate of ovarian reserve and are currently used in clinical practice before COS, there is still no consensus on the exact relationship between these markers and the quantity of the remaining primordial follicle pool, the quality, or both. Despite the validity of FSH, AMH and AFC for predicting ovarian reserve, there are patients with normal ovarian reserve markers who respond poorly to stimulation. In fact, it has been suggested that the ideal ovarian reserve test is the response of the ovaries to a normal or standard ovarian stimulation protocol (Karande and Gleicher, 1999; Tarlatzis et al., 2003; Penarrubia et al., 2005a,b) . Moreover, even though previous studies have tried to correlate ovarian reserve markers with clinical outcomes such as pregnancy and menopause, no accurate predictive models for those outcomes based on these markers have been validated. Thus, women's natural fertility cannot be predicted using these measurements (Dillon and Gracia, 2013; Hansen, 2013) .
The total oocyte number is established very early in life. Afterwards, there is a gradual loss of ovarian reserve during reproductive life until oocyte availability becomes limiting at the menopause. Although there is a large genetic component to the ovarian reserve, some influences during fetal life such as the maternal endocrine or nutritional milieu (Cresswell et al., 1997; Ibanez et al., 2000 Ibanez et al., , 2002 and other environmental factors may be of outstanding importance for a correct prenatal development of the total primordial follicle pool (Zenzes et al., 1997; Fuentes et al., 2010) . The combination of early and later life influences have the potential to lead to diminished ovarian reserve, compromising fertility in reproductive years and altering age at natural menopause (Richardson et al., 2014) .
AGD is one of the most sensitive markers of in utero exposures to environmental endocrine-disrupting chemicals (EDC) and, for this reason, it is routinely used in animal toxicology studies as a biomarker of prenatal contact to such compounds (Foster, 2006; Gray et al., 2006) . Previous animal studies have shown that fetal exposure to exogenous androgen or estrogen substances (including EDC) can alter the development of the female reproductive tract (Smith et al., 2009; Moyer and Hixon, 2012) . For instance, it has been shown that bisphenol A (BPA), which may have both estrogenic and anti-androgenic properties, may disrupt and alter ovarian function (Zhang et al., 2012) .
Besides, recent research has demonstrated that BPA exposure alters early oogenesis and follicle development in nonhuman primate fetal ovaries (Hunt et al., 2012) . In addition to that, Swan and colleagues showed a strong inverse correlation between prenatal environmental exposure to anti-androgenic phthalates and shorter male AGD in human infants (Swan et al., 2005; Swan, 2008) . According to these findings, AGD can be considered a reliable link between prenatal hormonal milieu and adult reproductive function in human males. Notwithstanding, less is known about AGD in human females. Some publications focusing on women at reproductive age have shown that AGD length is related to female reproductive function (Mendiola et al., 2012; Barrett et al., 2015; Mira-Escolano et al., 2014a,b) . More recently, it has been reported that women with PCOS present longer AGD measurements (Wu et al., 2017) , and that newborn daughters of women with PCOS also exhibit longer AGD (Barrett et al., 2018) . Furthermore, a strong association between shorter AGD measurements and the presence of endometriosis (an estrogen-dependent disease) has also been reported (Mendiola et al., 2016) . Despite such revealing studies, there is still controversy over what AGD means in humans (Foster et al., 2017 One potential limitation of the use of these measures as biomarkers in childbearing-age women, is the possibility that they may vary with the dramatic cyclical changes in reproductive hormone concentrations across the menstrual cycle or lifespan. The similar proportional increase in AGD in boys and girls during the first 2 years of life supports the growth of peritoneum in proportion to overall body size. However, the period of rapid increase in AGD during the first 3 months suggests that the postnatal surge in testosterone production may also contribute to changes in AGD (Thankamony et al., 2009) . A rodent study found that AGD was longer in diestrus than metestrus (Dusek and Bartos, 2012) and also animal data showed changes in AGD when postnatal androgen exposure is altered (Mitchell et al., 2015) , supporting the hypothesis that the mini-puberty plays a part in postnatal AGD development. In a study of adult women, the use of hormonal contraception predicted shorter AGD, further suggesting that adult circulating hormone levels could affect the measurements (Mendiola et al., 2012) . Unfortunately, in that cross-sectional study all AGD measurements were taken during the early follicular phase, so cyclical variation could not be evaluated. In this line of research, a more recent study has shown that AGD is stable across the women´s menstrual cycle . Longitudinal data for AGD measurements from infancy to adulthood are not available. Nevertheless, it has been speculated that large increases in AGD occur during puberty, in association with the development of the external genitalia. During the adult life, the AGD remains unchanged in males, but there is data that suggests a decrease in AGD in females following menopause (Thankamony et al., 2016) . In our study, the hormonal treatment was short in time, so it is unlikely that it could affect the AGD measures. In addition, in case any modifications occurred, they would have been similar in the three groups studied.
The current investigation prospectively compared AGD AC and AGD AF with ovarian reserve markers as predictors of ovarian response after COS for IVF/ICSI using a prospective observational cohort study. As demonstrated in previous works (Wainstock et al., 2017; Wu et al., 2017) , we found a positive correlation between AGD AC and AGD AF , and also between both measurements and BMI. Anogenital distances showed a moderate and significant relationship with the number of oocytes retrieved and also with the AFC, AMH and the OSI, which is considered a better response marker to gonadotropins than the number of oocytes obtained (Li et al., 2014) . Moreover, AGD AC showed an acceptable predictive value for poor response, similar to the most used ovarian response markers. These findings provide additional support to consider AGD as a useful anthropometric biomarker of intrauterine hormonal milieu for epidemiological and clinical studies. Although AGD AF was significantly different between poor responders and high responders, it actually exhibited a lower predictive capacity for poor response than AFC and AMH. In this regard, it has been suggested that the measurement of AGD AF tends to be more difficult due to uncertainty in the appropriate landmarks (Sanchez-Ferrer et al., 2017) . For instance, research in newborns has shown great differences in AGD AF between centers Swan et al., 2015) .
The main strength of our study is based in the novelty of the topic and its accurate methodological design. All the patients included underwent their first COS for IVF/ICSI, and that avoids any possible bias from experience of ovarian response to gonadotropin treatment in previous cycles. In addition, biases regarding possible basal modifications in AGD were taken into account and a part from having excluded patients with previous deliveries or ovarian/genital surgery, women with PCOS and endometriosis were also excluded from the study, as both entities have been related to present changes in AGD. Concerning the variability of AGD between the different observers that measured each distance, it must be taken into account that in order to reduce the intra and interobserver variability, only two gynecologists unaware of the ovarian response of the patient were responsible for all measurements, and that both distances were taken three times so the mean was reflected.
Nevertheless, this study presents some limitations that deserve to be commented: first of all, measurement or selection biases might have been possible and must always be considered. Secondly, the population used for this study was a highly selected group of infertile women who underwent their first COS for IVF. For this reason, the findings of the study must be interpreted with caution, as they may not be applicable for all (fertile) women. Thirdly, no data on the lifestyle of the study patients was available, so no conclusions on AGD can be drawn regarding this point. It is also noteworthy to highlight that AGD was measured after ovarian stimulation. Although all patients were in the same conditions to avoid measurement biases, it is not known whether the hormonal environment after a short period of COS could have altered AGD. Finally, information on specific exposures in utero or pregnancy complications of the study participants was lacking.
In conclusion, our results provide the first evidence of an association between a biomarker of hormonal prenatal environment and ovarian response to COS in patients undergoing IVF/ICSI, suggesting that the ovarian follicular pool could be affected by endocrine disruptors in prenatal life. Anogenital distance did not demonstrate an ovarian response predictive capacity better than the AMH levels and the AFC, so it would not be justified to incorporate this measure into daily clinical practice. Future research is needed to confirm these results and to understand the role of prenatal exposures in ovarian reserve.
